Fexallegra 10 Coated Tablets 120mg,Fexallegra 10 Compresse Rivestite 120mg,Sanofi Spa

“ACTIVE INGREDIENTS
Fexofenadine.
Excipients
Tablet core: microcrystalline cellulose; pregelatinized corn starch; croscarmellose sodium; magnesium stearate. Coating film: hypromellose; povidone; titanium dioxide (E171); colloidal silicon anhydrous; macrogol 400; iron oxide (E172).
DIRECTIONS
This medicine is indicated in adults and in children from 12 years of age for the symptomatic treatment of seasonal allergic rhinitis.
CONTRAINDICATIONS/EFF.SECONDARY
The medicine is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients listed.
DOSAGE
Adults: The recommended dose of fexofenadine hydrochloride for adults is the formulation appropriate for administration and dosage in this population. Special Populations: Studies conducted in at-risk patient populations (elderly, patients with renal liver failure) indicate that there is no need to adjust the dose of fexofenadine hydrochloride in these patients. This is 120 mg once daily, before meals. Fexofenadine is the pharmacologically active metabolite of terfenadine. Children 12 years of age and older: The recommended dose of fexofenadine hydrochloride for children 12 years of age and older is 120 mg one voltaal day, before meals. Children under 12 years of age: The effectiveness and safety of fexofenadine hydrochloride 120 mg no sonostar have been studied in children under 12 years of age. In children from 6 to 11 years: fexofenadine hydrochloride 30 mg tablets i’l
STORAGE
The drug does not require special precautions for preservation.
WARNINGS
As with most drugs, new data relating to elderly individuals and patients with impaired renal-liver function are limited. Fexofenadine hydrochloride should be administered with caution to these groups of subjects. Patients suffering from or undergoing cardiovascular disease should be aware that antihistamines, as a class of drugs, have been associated with adverse reactions such as tachycardia and increased heart rate.
INTERACTIONS
The fexofenadine does not undergo liver biotrasformazioni and therefore I am not observed after treatment in combination with erythromycin or ketoconazole, it seems to be caused by an increase in gastrointestinal absorption and, accordingly, a decrease in both escrezionebiliare gastrointestinal secretion. It was not osservatainterazione between fexofenadine and omeprazole. However, taking antacids containing aluminum and magnesium hydroxide 15 minutes before taking fexofenadine hydrochloride resulted in decreased bioavailability’ most likely to be associated with the gastrointestinal tract. And it is advisable that there be an interval of 2 hours between taking fexofenadine hydrochloride and antiacidnteragira with other drugs at the level of liver mechanisms. And it was containing aluminum and magnesium hydroxide. It was found that the administration of modern fexofenadinacloridrato and erythromycin or ketoconazole increases the plasma level of fexofenadine by 2-3 times. These changes were not accompanied by any effect on the QT interval and were not associated with an increase in adverse reactions compared to what was observed with the same medications prescribed individually. Animal studies have shown that increased plasma levels of fexofenadi
SIDE EFFECTS
It was used in the following frequency class when the following side effects were reported by post-marketing applicabilglianza. The frequency with which they occur is not noticeable. Immune system disorders: hypersensitivity reactions with symptoms of tipoangioedema, chest tightness, shortness of breath, hot flashes and systemic anaphylaxis. Mental disorders: insomnia, nervousness, sleep disturbidel or nightmares/exceeding dreams (paroniria). Heart disease: tachycardia, palpitations. Gastrointestinal pathologies: diarrhea. Diseases of the skin and subcutaneous tissue: rash, urticaria and itching. Reporting of adverse reactions is suspicious that occur after the drug is resolved and this is important because it allows une: very often >= 1/10; general >= 1/100 a = 1/100monitoraggio constant benefit/risk ratio of the drug.0, a = 1/10,000 and PREGNANCY AND LACTATION
There are no adequate data on the use of fexofenadine hydrochloride nelleadina hydrochloride is not recommended during breastfeeding. Women during pregnancy. Limited animal studies show no harmful effects, direct or indirect effects on pregnancy, embryo/fetal development, childbirth or postnatal development. Fexofenadine hydrochloride should not be used during pregnancy unless absolutely necessary. There are no data on concentrations in breast milk after taking fexofenadine hydrochloride. However, when terfenadine was administered to mothers during lactation, fexofenadine was found to pass into breast milk. Therefore the use of fexofen”